{
  "19311045-DS-17": " \nName:  ___                      Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adverse Drug Reactions\n \nAttending: ___\n \nChief Complaint:\nback pain, abdominal distension, L leg swelling\n \nMajor Surgical or Invasive Procedure:\nNone\n\n \nHistory of Present Illness:\n___ admitting MD:\n\n___ with Hx ovarian cancer s/p chemo, metastatic to spine c/b T5\ncompression fracture s/p fusion and laminectomy ___ who\npresented to the ED with acute onset back pain, abdominal\ndistention, and L leg swelling.\n\nIn regards to her back pain, she was recently discharged from\n___ on ___ s/p T5 fusion and laminectomy on ___. She had been\non OxyContin & oxycodone at home for back pain control but this\nmorning had an acute worsening of her pain to the point where \nshe\nwas unable to sit up or stand. She has also had worsening\nabdominal distention and poor appetite, taking in some food and\nliquids but limited by abdominal fullness. No fevers, no bowel\nincontinence, no saddle anesthesia, chronic Foley since spinal\nsurgery present. No bowel movement since ___ but has been\npassing gas, no nausea or vomiting. \n\nShe was recently admitted ___ when she presented for back\npain and urinary retention. She was found to have a pelvic mass,\na T5 compressive lesion on MRI, and numerous lesions on CT\nconcerning for metastatic cancer. She underwent biopsy which\nshowed poorly differentiated metastatic adenocarcinoma, \nsuspected\novarian source. She was started on carboplatin (C1D1 ___. \nHer\ncourse was complicated by urinary retention requiring Foley,\nconstipation, and PE for which she was started on apixaban.\n\nIn the ED,  \n- Initial Vitals:  T 99.3 HR 120 BP 111/77 RR 16 O2 98% RA\n- Exam:  Diffuse abdominal tenderness w/ voluntary guarding, 4 \nin\necchymosis on abdomen. Cool extremities. Tenderness in mid-T\nspine. \n- Labs:  WBC 20.1, Hgb 8.3, Plt 37, K 6.9, Ca ___, uric acid\n12.0, Na 127, lactate 8.3, VBG 7.29/43, HCO3 17, BUN 50, Cr 1.3,\nALT 193, AST 306, AlkPhos 439, TBili 1.9, LDH 4190 \n- Imaging:  \n--- ULE - no evidence of DVT, sluggish flow in L common femoral\nvein. \n--- ECG: no T wave abnormalities \n- Consults:  Spine \n- Interventions: IV Dilaudid 1mg x 2, Zosyn 4.5g, allopurinol\n___, rasbirucase, insulin/dextrose, NS x 2L\n\nWhile in the ED, labs were found to be significant for elevated\nuric acid (12), K (6.8), phos (5.4) leading to a c/f tumor lysis\nsyndrome. Her primary oncologist was contacted, agreed w/ c/f \nTLS\nthough unusual given solid tumor, and suggested renal U/S, LFTs\nand lactate.\n\nOn arrival to the FICU, she reports her abdominal and back pain\nhave improved. No nausea. No shortness of breath or chest pain.\n \nPast Medical History:\nPMH/PSH:  \n========\n___ s/p T5 vertebrectomy, T3-7 robotic posterior \nlami/fusion, bilateral T5 nerve root ligation & anterior column \nreconstruction\nPE on eliquis\n\nONCOLOGY HX:\n============\nShe presented on ___ with abdominal pain and\ninability to urinate. \n\nDuring work up for potential cord compression a pelvic mass was \nappreciated by OB-GYN during IUD removal for MRI evaluation. MRI \n\nrevealed a T5 compressive lesion with severe canal narrowing and \n\ncompression of the spinal cord. Further work up including CT \ntorso showed multiple other lesions including lesions in the \nliver, lung, and redemonstration of the pelvic lesion. Patient \nunderwent T5 vertebrectomy, T3-7 robotic posterior lami/fusion, \nbilateral T5 nerve root ligation & anterior column \nreconstruction without complication. Patient was subsequently \ntransferred to ___ for further evaluation and treatment of \nsuspected malignancy. Bone biopsy done at the time of spinal \nsurgery revealed poorly differentiated metastatic \nadenocarcinoma. It was felt that this was from a GYN source, \nmost suspicious for ovarian. She was treated with carboplatin \n___. Patient was found to have a PE on ___ and was treated \nwith heparin gtt before being transitioned to apixaban.\n\n \nSocial History:\n___\nFamily History:\nUnknown \n \nPhysical Exam:\nADMISSION PHYSICAL EXAM:\nVS: T 98.6 HR 108 BP 125/81 RR 19 O2 98% RA  \nGENERAL: Cachectic appearing.\nHEENT: PERRL. Sclera anicteric and without injection. Mucous\nmembranes appear dry.  \nNECK: Thyroid is normal in size and texture, no nodules. No\ncervical lymphadenopathy. No JVD.  \nCARDIAC: Tachycardic, regular rate. Audible S1 and S2. No\nmurmurs/rubs/gallops.  \nLUNGS: Clear to auscultation bilaterally. No wheezes, rhonchi or\nrales. No increased work of breathing.  \nBACK: Midline thoracic incision appears well-healing, c/d/i. No\nspinous process tenderness. No CVA tenderness.  \nABDOMEN: Distended, firm, nontender without rebound or guarding. \n\nEXTREMITIES: ___ pitting edema R > L, RLE slightly cool. 1+ DP\npulse in RLE, 2+ in LLE. \nSKIN: No rash.  \nNEUROLOGIC: Sleepy but awakes to voice and answers questions\nappropriately. AOx3. CN2-12 intact. ___ strength throughout.\n\nDISCHARGE PHYSICAL EXAM:  \nVITALS: \n24 HR Data (last updated ___ @ 1039)\n    RR: 12 (___)\nGeneral:  NAD, Resting in bed comfortably\nHEENT:  MMM, no OP lesions \nCV:  RR, NL S1S2 no S3S4, no m/r/g\nPULM:  CTAB, No C/W/R, No respiratory distress\nABD:  BS+, soft, NTND, palpable firm mass\nin lower abdomen\nEXT: 1+ LLE edema to knee, warm, LLE cooler to touch than R\nSKIN: dry, no obvious rashes\nNEURO: lethargic, though will wake up to audible stimuli, PERRL.\nACCESS: RUE ___\n \nPertinent Results:\nAdmission Labs:\n___ 10:40AM BLOOD WBC-20.1* RBC-3.72* Hgb-8.3* Hct-27.8* \nMCV-75* MCH-22.3* MCHC-29.9* RDW-25.8* RDWSD-61.2* Plt Ct-37*\n___ 10:40AM BLOOD Neuts-88.1* Lymphs-4.8* Monos-4.9* \nEos-0.1* Baso-0.1 NRBC-1.2* Im ___ AbsNeut-17.65* \nAbsLymp-0.97* AbsMono-0.99* AbsEos-0.03* AbsBaso-0.02\n___ 10:40AM BLOOD Plt Ct-37*\n___ 08:26PM BLOOD ___ PTT-25.9 ___\n___ 10:40AM BLOOD Glucose-111* UreaN-49* Creat-1.3* Na-127* \nK-6.9* Cl-88* HCO3-18* AnGap-21*\n___ 01:27PM BLOOD ALT-193* AST-306* LD(LDH)-4190* \nAlkPhos-439* TotBili-1.9*\n___ 10:40AM BLOOD Calcium-11.8* Phos-5.4* Mg-2.5\n___ 03:24PM BLOOD ___ pO2-33* pCO2-43 pH-7.29* \ncalTCO2-22 Base XS--6\n___ 03:24PM BLOOD Lactate-8.3*\n\n___ CT ABD & PELVIS\n1. Interval increase in size of a large heterogeneous pelvic\nmass, now measuring up to 16 cm, previously 11 cm. \n2. Interval development of innumerable hypodense liver lesions,\nconcerning for progressive metastatic disease. \n3. 1.8 cm left renal masses may represent metastatic disease. \n4. Mild interval worsening of moderate left hydronephrosis, in\nthe setting of a large pelvic mass. \n5. Unchanged diffuse lymphadenopathy, as detailed above. \n\n___ MRI SPINE\n1. Interval increase in size of a large heterogeneous pelvic\nmass, now measuring up to 16 cm, previously 11 cm. \n2. Interval development of innumerable hypodense liver lesions,\nconcerning for progressive metastatic disease. \n3. 1.8 cm left renal masses may represent metastatic disease. \n4. Mild interval worsening of moderate left hydronephrosis, in\nthe setting of a large pelvic mass. \n5. Unchanged diffuse lymphadenopathy, as detailed above. \n\n___ LLE DOPPLER\nNo evidence of deep venous thrombosis in the left lower \nextremity\nveins.  \nSuspect sluggish flow within the left common femoral vein. \n\n___ CXR\nSpinal hardware is in place.  Right PICC line tip is most likely \nat the \ncavoatrial junction.  Heart size and mediastinum are \nunremarkable.  Lungs \noverall clear.  No pleural effusion.  No pneumothorax. \n\n___ RENAL US\nIMPRESSION:  \nSimilar moderate left hydronephrosis compared to the recent CT \nstudy and \nultrasound.  Mild right hydronephrosis likely similar to the \nprior CT given differences in contrast excretion. \n\n  \n\n \nBrief Hospital Course:\n___ with PMH of ovarian cancer s/p chemo, metastatic to spine \nc/b T5 compression fracture s/p fusion and laminectomy ___, \nPE on Eliquis who presented to the ED withacute onset back pain, \nabdominal distention, and L leg swelling. In the ED, patient was \nnoted to have elevated uric acid, hyperkalemia, lactic acidosis, \nand hyperphosphatemia c/f TLS. She was admitted to ___ given \npoor urine outpatient and lactic acidosis in setting of \nsuspected TLS.\n\nIn the ICU, patient received aggressive fluid hydration and \nrasburicase with improvement of hyperuricemia. Her Hgb \ndowntrended, though to be dilutional in setting of 4L IVF. She \nhad persistent lactic acidosis and multisystem organ failure and \nas such, a family meeting was held with her primary oncologist. \nPatient was made CMO with a focus on comfort. Patient was \nstarted on a dilaudid gtt for pain with improvement of symptoms. \nPatient died on ___ at 11:45AM while receiving CMO with \nfamily at bedside.\n\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. OxyCODONE SR (OxyCONTIN) 30 mg PO Q12H \n2. Bisacodyl 10 mg PO/PR DAILY:PRN Constipation - Second Line \n3. Famotidine 20 mg PO DAILY \n4. Lidocaine 5% Patch 1 PTCH TD QAM back pain \n5. Milk of Magnesia 30 mL PO Q6H:PRN Constipation - First Line \n6. Ondansetron 4 mg PO Q8H:PRN Nausea/Vomiting - First Line \n  Reason for PRN duplicate override: Alternating agents for \nsimilar severity\n7. OxyCODONE (Immediate Release) 10 mg PO Q2H:PRN Pain - \nModerate \n8. Polyethylene Glycol 17 g PO BID \n9. Senna 17.2 mg PO BID \n10. Simethicone 40-80 mg PO QID:PRN abdominal pain \n11. Dexamethasone 4 mg PO BID \n12. Apixaban 5 mg PO BID \n\n \nDischarge Medications:\nN/A\n \nDischarge Disposition:\nExpired\n \nDischarge Diagnosis:\nOvarian Cancer\nTLS\nAcute Kidney Injury\nMultisystem Organ Failure\nPE\n\n \nDischarge Condition:\nExpired\n\n \nDischarge Instructions:\nAs above\n \nFollowup Instructions:\n___\n"
}